Arca
Skip to content
Tools
Tools

Label Changes: Zelboraf (vemurafenib)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Zelboraf label DailyMed has published, from Genentech, Inc., and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 25
  • Sections changed, version 28 to 29: 2

What changed from version 28 to version 29

Dec 10, 2025 to Sep 4, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Adverse reactionsChanged ยท 4 words added
  2. Untitled sectionChanged ยท 1 word added, 1 removed

Adverse reactions

Changed4 words added
83 unchanged lines
The median treatment duration for ECD patients in this study was 14.2 months. Table 3 presents adverse reactions reported in at least 20% of BRAF V600 mutation-positive ECD patients treated with ZELBORAF.
In Trial 4, the most commonly reported adverse reactions (> 50%) in patients with BRAF V600 mutation- positive ECD treated with ZELBORAF were arthralgia, rash maculo-papular, alopecia, fatigue, electrocardiogram QT interval prolonged, and skin papilloma. The most common (โ‰ฅ 10%) Grade โ–ฏโ‰ฅ 3 adverse reactions were squamous cell carcinoma of the skin, hypertension, rash maculo-papular, and arthralgia.
The incidence of adverse reactions resulting in permanent discontinuation of study medication was 32%.
57 unchanged lines
Musculoskeletal and connective tissue disorders: Dupuytren's contracture and plantar fascial fibromatosis [see Warnings and Precautions (5.12)].
Immune system disorders: Sarcoidosis

Untitled section

Changed1 word added, 1 removed
Distributed by: Genentech USA, Inc. A Member of the Roche Group 1 DNA Way South San Francisco, CA 94080-4990
ZELBORAF is a registered trademark of Genentech, Inc. Co-promoted by: Genentech USA, Inc. and Daiichi Sankyo, Inc. ยฉ20202026 Genentech, Inc.

Unchanged: Indications and usage, Dosage and administration, Dosage forms and strengths, Contraindications, Warnings and precautions, Drug interactions, Use in specific populations, Overdosage, Description, Clinical pharmacology, Nonclinical toxicology, Clinical studies, How supplied, Patient counseling information, Medication guide, Untitled section, PRINCIPAL DISPLAY PANEL - 240 mg Tablet Bottle Carton.

Every version

25 versions of set 38eea320-7e0c-485a-bc30-98c3c45e2763, newest first.

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.